H. Phan

641 total citations
22 papers, 244 citations indexed

About

H. Phan is a scholar working on Molecular Biology, Surgery and Genetics. According to data from OpenAlex, H. Phan has authored 22 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 4 papers in Surgery and 4 papers in Genetics. Recurrent topics in H. Phan's work include Muscle Physiology and Disorders (12 papers), Neurogenetic and Muscular Disorders Research (3 papers) and RNA modifications and cancer (3 papers). H. Phan is often cited by papers focused on Muscle Physiology and Disorders (12 papers), Neurogenetic and Muscular Disorders Research (3 papers) and RNA modifications and cancer (3 papers). H. Phan collaborates with scholars based in United States, United Kingdom and Spain. H. Phan's co-authors include R. Rodney Howell, Jennifer L. Taylor, Gary J. Bassell, Wilfried Rossoll, Claudia Fallini, Jeannie Visootsak, Paul Donlin-Asp, Jazmin Campos, Roberta M. Leu and Rebecca Kronk and has published in prestigious journals such as Nature Communications, Neurology and Cell Reports.

In The Last Decade

H. Phan

18 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Phan United States 8 163 121 58 34 21 22 244
Rosángel Cruz United States 9 123 0.8× 259 2.1× 142 2.4× 21 0.6× 21 1.0× 21 315
Biljana Dumevska Australia 6 204 1.3× 24 0.2× 36 0.6× 23 0.7× 13 0.6× 27 225
Maria Sframeli Italy 11 269 1.7× 282 2.3× 171 2.9× 26 0.8× 11 0.5× 27 441
Yasuo Hachiya Japan 8 104 0.6× 70 0.6× 35 0.6× 31 0.9× 16 0.8× 12 200
Bo Hoon Lee United States 7 128 0.8× 136 1.1× 102 1.8× 95 2.8× 16 0.8× 13 285
Marc‐Olivier Deguise Canada 13 246 1.5× 307 2.5× 118 2.0× 13 0.4× 6 0.3× 25 405
Crystal M. Proud United States 9 170 1.0× 124 1.0× 68 1.2× 58 1.7× 3 0.1× 25 281
Elke Hobbiebrunken Germany 8 133 0.8× 45 0.4× 37 0.6× 76 2.2× 34 1.6× 11 268
Veronica McInerney Ireland 6 116 0.7× 31 0.3× 31 0.5× 42 1.2× 8 0.4× 27 214
Filippo Buccella Italy 5 160 1.0× 53 0.4× 11 0.2× 32 0.9× 15 0.7× 9 222

Countries citing papers authored by H. Phan

Since Specialization
Citations

This map shows the geographic impact of H. Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Phan more than expected).

Fields of papers citing papers by H. Phan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Phan. The network helps show where H. Phan may publish in the future.

Co-authorship network of co-authors of H. Phan

This figure shows the co-authorship network connecting the top 25 collaborators of H. Phan. A scholar is included among the top collaborators of H. Phan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Phan. H. Phan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Phan, H., Ayesha Ahmad, Janet A. Thomas, et al.. (2024). Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia. The Journal of Clinical Pharmacology. 65(5). 575–587. 1 indexed citations
2.
Campbell, Craig, H. Phan, Perry B. Shieh, et al.. (2024). 225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skipping. Neuromuscular Disorders. 43. 104441.67–104441.67.
3.
4.
Sansone, Valeria, H. Phan, Tracey Willis, et al.. (2024). 429P Givinostat in Duchenne muscular dystrophy: natural history comparison applying propensity score matching. Neuromuscular Disorders. 43. 104441.300–104441.300.
5.
Tavakoli, Norma P., Sunju Park, Michele Caggana, et al.. (2023). Multi-Laboratory Evaluation of Prototype Dried Blood Spot Quality Control Materials for Creatine Kinase-MM Newborn Screening Assays. International Journal of Neonatal Screening. 9(1). 13–13. 3 indexed citations
6.
Lahmann, Ines, Benjamin R. Rost, Angélica García-Pérez, et al.. (2023). Efficient generation of a self-organizing neuromuscular junction model from human pluripotent stem cells. Nature Communications. 14(1). 8043–8043. 15 indexed citations
7.
Connolly, Anne M., Craig M. Zaidman, John F. Brandsema, et al.. (2023). Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 10(4). 685–699. 11 indexed citations
8.
Collins, Sarah, H. Phan, Alan J. Russell, et al.. (2023). P255 Effects of EDG-5506, a fast myosin modulator, on function and biomarkers of muscle damage in adults with Becker muscular dystrophy (BMD). Neuromuscular Disorders. 33. S146–S147.
9.
Butterfield, Russell J., Kristin M. Conway, Nicholas E. Johnson, et al.. (2022). Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non‐ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle & Nerve. 66(1). 15–23. 6 indexed citations
10.
Phan, H., et al.. (2022). Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy. Human Gene Therapy. 34(9-10). 430–438. 14 indexed citations
11.
Campbell, Craig, Katherine D. Mathews, Emanuel Palatinsky, et al.. (2022). eP213: Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results. Genetics in Medicine. 24(3). S133–S133. 2 indexed citations
12.
Kwon, Jennifer M., Kapil Arya, Nancy L. Kuntz, et al.. (2022). An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Annals of Clinical and Translational Neurology. 9(6). 810–818. 26 indexed citations
13.
Verma, Sumit, et al.. (2021). Anti-Adeno-Associated virus (AAV) neutralizing antibody (Nab) titers in Duchenne muscular dystrophy (DMD) (5013). Neurology. 96(15_supplement). 1 indexed citations
14.
Iannaccone, Susan T., H. Phan, Volker Straub, et al.. (2021). DMD - TREATMENT. Neuromuscular Disorders. 31. S94–S95. 2 indexed citations
15.
Reinertsen, Erik, et al.. (2019). Use of a wearable device to assess sleep and motor function in Duchenne muscular dystrophy. Muscle & Nerve. 61(2). 198–204. 10 indexed citations
16.
Wagner, Kathryn R., H. Phan, Laurent Servais, et al.. (2019). O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial. Neuromuscular Disorders. 29. S124–S124. 4 indexed citations
17.
Donlin-Asp, Paul, Claudia Fallini, Jazmin Campos, et al.. (2017). The Survival of Motor Neuron Protein Acts as a Molecular Chaperone for mRNP Assembly. Cell Reports. 18(7). 1660–1673. 58 indexed citations
18.
Karroum, Elias G., et al.. (2016). Perfect Periodicity: To Be Or Not To Be Periodic Leg Movements. Journal of Clinical Sleep Medicine. 12(3). 452–455. 1 indexed citations
19.
Phan, H., et al.. (2015). Newborn screening for spinal muscular atrophy: Anticipating an imminent need. Seminars in Perinatology. 39(3). 217–229. 51 indexed citations
20.
Phan, H., et al.. (2015). Sleep profiles in children with down syndrome. American Journal of Medical Genetics Part A. 167(8). 1830–1835. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosángel Cruz Breakdown of academic impact, for papers by Biljana Dumevska Breakdown of academic impact, for papers by Maria Sframeli Breakdown of academic impact, for papers by Yasuo Hachiya Breakdown of academic impact, for papers by Bo Hoon Lee Breakdown of academic impact, for papers by Marc‐Olivier Deguise Breakdown of academic impact, for papers by Crystal M. Proud Breakdown of academic impact, for papers by Elke Hobbiebrunken Breakdown of academic impact, for papers by Veronica McInerney Breakdown of academic impact, for papers by Filippo Buccella
Rankless by CCL
2026